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Whilst various remedial human monoclonal antibodies have been developed to treat the potentially 
life-threatening systemic complications associated with anthrax infection, an optimal and universally 
effective administration route has yet to be established. In the later stages of infection when antibody 
administration by injection is more likely to fail one possible route to improve outcome is via the 
use of an antibody-bound, adsorbent haemoperfusion device. We report here the development of 
an adsorbent macroporous polymer column containing immobilised B. anthracis exotoxin-specific 
antibodies, PANG (a non-glycosylated, version of a plant-produced human monoclonal antibody) 
and Valortim (a fully human monoclonal N-linked glycosylated antibody), for removal of anthrax 
protective antigen (PA) from freshly frozen human plasma and human whole blood. In addition, we 
have demonstrated that continuous extracorporeal blood recirculation through a Valortim-bound 
haemoperfusion column significantly reduced the blood plasma concentration of anthrax PA over 2 
hours using an in vivo PA rat infusion model. This work provides proof-of-concept evidence to support 
the development of such alternative detoxification platforms.
Anthrax infection is caused by exposure to the micro-organism Bacillus anthracis (B. anthracis)1. The virulence 
of the bacteria is due primarily to the production of a tripartite toxin which as the name suggests is comprised 
of three elements: a non-toxic cell receptor binding protein known as “protective antigen” (PA) and two catalytic 
proteins known as “lethal factor” (LF) and “edema factor” (EF). The toxin follows the AB model, the A moiety 
comprising the catalytic subunits LF and EF, while the B moiety, PA, serves to translocate either EF or LF into 
the cytosol2. The B moiety is so named owing to its role as the key protective immunogen in the current human 
vaccine. It has been proposed that PA binds to ubiquitous cell surface receptors, at least two of which have been 
identified, anthrax/tumour endothelial marker 8 and capillary morphogenesis protein, whereupon it is cleaved 
by the cell-surface protease, furin, to expose the A moiety binding site3,4. Following proteolytic activation, PA 
forms a membrane-inserting heptamer that translates LF and EF into the cytosol. There is experimental evidence 
to suggest that this might not be the only model of toxin interaction and uptake5. In addition to forming protein 
complexes on cell surfaces, PA and LF are able to form a biologically active complex in the serum of a range of 
animal species, including primates, which is able to kill susceptible macrophages5,6.
Given the central role of this toxin in the disease process it is not surprising that the current recommended 
treatment for infected individuals is a prolonged regimen of antibiotic treatment combined with immunisation 
with a PA-based vaccine to eliminate any residual traces of the pathogen due to the ability of spores to persist in 
the lungs7,8. To be effective treatment must be started as soon as possible as animal studies have shown that once 
the level of circulating toxin exceeds a critical threshold antibiotics are no longer likely to be effective9,10. The 
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current countermeasures for anthrax are vaccines, antibiotics and antibodies. They are an integral part of med-
ical care, but all have limitations. Vaccines are an effective means of protection provided the individual has had 
the time necessary to generate a protective, antibody-based response11. Antibiotics have the advantage that they 
can be used to both protect and treat post-exposure by controlling the bacterial infection, but they fail to clear 
released toxins from the bloodstream, and antibiotic-resistant strains may not be effectively thwarted12.
Over the past decade, extensive research has been undertaken to develop therapeutic antibodies which target 
anthrax toxin components and can provide protection when given alone or in combination with antibiotic treat-
ment13–16. Several recombinant monoclonal antibodies (mAbs) such as PANG17, Valortim18,19, and Raxibacumab20 
have been developed which bind to PA and have been shown to protect infected animals. They act by inhibiting 
different stages of the intoxication process, including the inhibition of PA-receptor binding, proteolytic cleavage, 
oligomerisation, internalisation, and EF/LF binding. Raxibacumab which has been approved by the FDA for the 
treatment of inhalational anthrax using the Animal Rule (US Food and Drug Administration 2012) increases 
survival in animal models when given pre-exposure21 and has demonstrated a survival benefit for exposed rabbits 
when administered in combination with antibiotics22.
Given the paucity of data on human inhalation of anthrax the post-exposure period for effective treatment of 
human disease remains unknown. In an effort to address this issue, Rubinson et al. extrapolated animal model 
data and estimated that that the co-administration of raxibacumab and antibiotic within 7 days of spore exposure 
would protect the majority (>80%) of individual23. To derive this estimate the authors made assumptions about 
the health status of the individuals prior to infection and while these assumptions may be appropriate for seg-
ments of society such as the military, they are unlikely to hold true for the vast majority of the civilian population. 
Indeed, while treatment with the antibody might completely neutralise the toxin, this alone may be insufficient 
to ensure the survival of infected individuals. Studies undertaken in animals have shown that infection with B. 
anthracis elicits many features of a septic disease and that while the toxin plays a central role in pathology the 
host’s own uncompensated inflammatory and coagulopathic responses also contribute to the process24,25. For 
example the release of B.anthracis cell wall peptidoglycan has been shown to trigger the production and release 
of pro-inflammatory TNF-alpha and IL-826. We hypothesize that a system capable of removing both PA and 
pro-inflammatory mediators would enhance the chance of survival of infected individuals. To advance the devel-
opment of such a system we are exploring the feasibility of attaching PA specific monoclonal antibodies to the 
surface of the cyrogel in a manner which optimizes its ability to remove PA from circulating blood.
Chemical immobilisation of monoclonal antibodies onto a solid supporting surface can be carried out using 
a number of approaches for selective purification of biological media27. Factors such as the size, surface chemis-
try, surface density and orientation of the immobilised antibodies strongly affects immunosorbent efficacy28–35. 
Immobilization should be done in a way that does not block the antibody’s active sites during antibody-antigen 
interaction. Protein-A is commonly used in antibody immobilization to correctly orientate the antibody through 
bond formation with the heavy chain region (Fc) of the antibody33,34. This leaves the flexible heavy and light chain 
regions (Fab) accessible for binding to antigen epitopes.
Blood detoxification by adsorption of anthrax toxins using chemically immobilised PA antibody bound to 
the internal surface of a macroporous interconnected cryogel column has yet to be explored. In our previous 
work, we investigated the synthesis of a range of macroporous cryogel adsorbents with tunable physical and 
mechanical properties for covalent immobilisation of anthrax toxin specific antibodies, PANG and Valortim, 
using protein-A affinity ligand. We demonstrated that protein-A bound poly(acrylamide-co-allyl glycidyl ether) 
(AAm-AGE) cryogels had the physical properties and capacity to bind antibody for the removal of anthrax toxin 
PA from phosphate buffered saline (PBS)36. In this article, we report for the first time the significantly increased 
removal of anthrax PA by covalently immobilised Valortim antibody on macroporous polyacrylamide-based 
cryogel columns from fresh frozen human plasma and freshly drawn human whole blood. In addition, a min-
iaturized extracorporeal circuit incorporating a plain and Valortim antibody bound cryogel, was used to filter 
blood in a Sprague-Dawley rat intravenous anthrax PA toxin infusion model in order to assess PA removal from 
blood over time.
Results
Material synthesis and porous morphology. Cylindrical macroporous poly(AAm-AGE) cryogel col-
umns were synthesized by co-polymerisation of monomers, acrylamide (AAm) and allyl glycidyl ether (AGE), 
using a cryogelation technique (Fig. 1A)36. During co-polymerisation N, N’-methylenebis(acrylamide) (MBA) 
was used as a crosslinker, while N, N, N’, N’-tetramethylethylenediamine (TEMED) and ammonium persulfate 
(APS) were used as a redox initiator pair to activate polymerisation. Mercury porosimetry and scanning electron 
microscopy (SEM) indicated a consistent porosity in the 10–100 μm range with smooth pore walls (Fig. 1B). 
Nitrogen adsorption isotherm measurements, obtained to characterise the porous structures of AAm-AGE cryo-
gel samples, exhibited a typical type-IV sorption isotherm profile that are indicative of mesoporosity (Fig. 1C). 
The pore size distribution profile for AAm-AGE cryogel revealed that the cryogel predominantly possesses mac-
ropores (Fig. 1B) and with some evidence of meso-pores (Fig. 1C), which accounts for the high surface area of 
this material. The surface epoxy groups on the AAm-AGE cryogel were activated by glutaraldehyde which intro-
duced aldehyde groups for covalent attachment of affinity ligand protein-A which was further used to link PANG 
and Valortim antibodies (Fig. 2)36.
Cryogel binding capacity and the impact of glycosylation on PANG vs Valortim binding and 
PA capture. The AAm-AGE cryogel has a large specific surface area (101 m2/g) on which proteins cova-
lently attach with a high protein binding capacity (96.4 ± 10.4 mg/g of adsorbent)36. Previous work demon-
strated that the glycosylated Valortim antibody (117 mg/g) bound significantly higher levels of PA from PBS 
(p < 0.05) than non-glycosylated PANG (108 mg/g) on the AAm-AGE-protein-A cryogel column36. In vitro PA 
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removal studies from human plasma and blood were carried out using a lab scale continuous circulation model 
(Fig. 3A and B) connected to Valortim or PANG-bound cryogel columns capable of capturing anthrax toxin PA 
by antibody-antigen interaction (Fig. 3C). An anti-PA sandwich enzyme-linked immunosorbent assay (ELISA) 
was used to demonstrate that tubing and cryogel controls without PA bound antibody did not remove significant 
levels of PA from plasma at any time point over the 60-minute recirculation period (Fig. 4A). All four control 
groups showed similar PA values at all sampling time points. In contrast, over the 60-minute recirculation period 
a significant reduction in plasma PA concentration was observed for both the AAm-AGE-Valortim cryogel col-
umns (1 to 0.15 μg/mL) and the AAm-AGE-PANG cryogel columns (1 to 0.33 μg/mL), with 85% and 67% reduc-
tion respectively. The final plasma PA concentration of the AAm-AGE-protein-A-Valortim group (0.15 μg/mL) 
was significantly reduced when compared to both the non-specific IgG mAb-bound AAm-AGE column (0.73 μg/
mL) and the tubing control (0.84 μg/mL). A similar significant reductions in final plasma PA concentration were 
observed for the AAm-AGE-protein-A-PANG group where a final concentration of 0.33 μg/mL was obtained. 
The removal of PA from human whole blood by Valortim-bound AAm-AGE cryogels showed results that were 
similar to those seen in plasma (Fig. 4B). Both the tubing control and non-specific IgG mAb-bound AAm-AGE 
cryogel groups did not remove PA from blood over the 60-minute recirculation at any time point and both groups 
had similar PA values throughout. As for the plasma experiments, the AAm-AGE-Valortim cryogel columns 
removed a significant amount of spiked PA from whole blood, removing 60% (1 to 0.40 μg/mL) and 72% (1 to 
0.28 μg/mL), at the 45 and 60-minute time points, respectively. This decrease in PA concentration was not sig-
nificant at earlier time points, but does show an increased removal over time, an observation that is typical of a 
kinetic process such as this. When compared with the final PA concentration in the non-specific IgG mAb-bound 
AAm-AGE and the tubing control, the AAm-AGE-protein-A-Valortim cryogels significantly reduced the whole 
blood PA concentration by 62% (0.75 μg/mL vs 0.28 μg/mL, p < 0.05) and 67% (0.85 μg/mL vs 0.28 μg/mL, 
p < 0.05), respectively.
In vivo studies to determine PA removal from rat blood. This work demonstrates that engineered 
antibodies crosslinked to cryogels bind PA toxin in vitro, and may be used as an effective means for in vivo 
PA toxin removal. To test this, miniaturized extracorporeal circuits incorporating either plain (AAm-AGE) or 
Valortim antibody-bound (AAm-AGE-Valortim) cryogel columns were set up in an in vivo rat model (Fig. 5A). 
Sprague-Dawley rats were infused intravenously with anthrax toxin PA and placed on extracorporeal circulation 
(2 hrs at 2 mL/min). Blood samples were collected at 0, 60 and 120 minutes and concentration of PA was meas-
ured by an anti-PA sandwich ELISA (Fig. 5B). It was first determined that intravenous (IV) infusion of PA toxin 
(100 μ/kg/hr over 1 hour) resulted in a significantly higher circulating concentration of PA in rats than intraperi-
toneal (IP) injection, although the circulating PA concentration decreased over the ensuing 2 hours, most likely 
due to tissue deposition (Fig. 5C). As a result, it was determined that a maintenance infusion of PA (40 μg/kg/
Figure 1. The process of cryogel formation and macro-meso pore size distribution. (A) The different stages that 
occur during cryogelation. (B) Macropore size distribution as determined by mercury porosimetry and inset 
SEM images showing internal porous architecture, Scale bar = 20 μm. (C) N2 adsorption isotherm with inset 
image representing mesopore size distribution.
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hr) was required to maintain elevated circulating PA toxin levels throughout the period of extracorporeal circuit 
treatment. Following the initial intravenous PA protein infusion (1 hr), the Valortim-bound column significantly 
reduced circulating PA concentrations by 79% (n = 5) over a subsequent 2 hr evaluation period, measured by an 
anti-PA sandwich ELISA (Fig. 5D). Over a 2-hour extracorporeal circuit treatment, a significant reduction in PA 
(p < 0.01) was observed in comparison with plain AAm-AGE columns (66%, n = 6) over the same time period 
(Fig. 5D). Further, various blood biochemistry analyte levels were monitored at the start and end of the circuit 
and showed no significant effects on blood biochemistry during the circuit treatment period (Fig. 6A–G). This 
data demonstrate that Valortim-bound cryogel columns are able to efficiently remove PA toxin from whole blood 
not only within in vitro studies, but also when used in vivo as an extracorporeal therapy.
Discussion
The device, designed in the current study to be used extracorporeally like dialysis, consists of a Valortim 
antibody-bound, highly interconnected macroporous polymeric AAm-AGE cryogel. It traps circulating anthrax 
toxin component PA and thus reduces the impact of the potent tripartite toxin on the unfortunate host. The 
interconnecting macroporous polymer structure offers a large surface area for antibody attachment and is formed 
by cryo-polymerisation. During synthesis polymerisation occurs at sub-zero temperatures as a result of a com-
plex process combining the crystallization of solvent (water) and the free radical co-polymerisation of AAm 
Figure 2. Schematic representation illustrating the glutaraldehyde activation approach utilized for protein-A 
conjugation and covalent immobilisation of monoclonal antibodies via protein-A on epoxy containing cryogel 
and subsequent crosslinking using dimethyl pimelimidate (DMP). Ethylenediamine was used as a donor of a 
spacer arm to improve binding between affinity ligand (protein-A) and antibody by overcoming any effect of 
steric hindrance.
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(monomer), MBA (crosslinker) and AGE. AGE is used as a minor co-monomer to introduce epoxy functional 
rings onto the porous cryogel surface and allow covalent attachment of the affinity protein-A36. Protein-A affinity 
ligand is linked to the epoxy-containing macroporous cryogel matrix with a 7-carbon spacer arm generated on 
the epoxy-activated porous surface using an ethylenediamine (EDA) and glutaraldehyde reaction, which is fur-
ther used to attach PANG and Valortim antibodies using dimethyl pimelimidate (DMP). The size and structure 
of the cryogel pores are controlled by two processes that occur simultaneously. The first is crystallization during 
cryogelation which is controlled by freezing conditions and the second is polymerisation, which is influenced 
mainly by the concentration of monomers, cross-linkers and the initiator system37–39. Part of the monomer solu-
tion reserved in the voids around the ice crystals remains unfrozen due to the concentration of the dissolved 
substances. The co-polymerisation and the formation of the cryogel matrix occurs in the unfrozen phase. Finally, 
melting of entrapped ice create the system of interconnected pores (Fig. 1A). In order to be used as a matrix to 
capture anthrax toxin PA, cryogels should have large and interconnected pores of a size greater than 10–15 μm. 
The study of pores in wet hydrogels presents a significant challenge40. Whereas the porosity and pore size distribu-
tion of a rigid porous material in the dry state are traditionally determined by mercury intrusion porosimetry37,41, 
there is no general method to determine pore size and pore structure in soft and highly hydrated systems.
We have demonstrated a synthesis route for an AAm-AGE cryogel which produces large pores, an intercon-
nected channel structure and a large surface area allowing antibodies to bind for blood-borne toxin removal. The 
concept was first developed in our previous work optimizing the structural performance of the cryogels them-
selves. This ultimately resulted in a high protein-A binding capacity, enabling optimal antibody loading through 
control of excessive steric hindrance36. Glyco-engineered antibodies exploit the common post-translational 
modification of glycosylation in the antibody’s Fc region to modulate effector function and stability, and ulti-
mately therapeutic efficacy. Antibody glycosylation, particularly in the Fc region of IgGs, has been extensively 
studied in health and disease and it has been shown that N-glycans are critical for antibody function. After 
60 minutes recirculation, the glycosylated Valortim antibody bound significantly higher levels of PA (p < 0.05) 
than non-glycosylated PANG on the AAm-AGE-protein-A cryogel column using fresh frozen human plasma 
and freshly withdrawn blood suggesting a potential role for in explaining the disparity. Additionally, the 
Valortim-bound columns showed a significantly increased ability (p < 0.05) to clear PA from plasma with respect 
Figure 3. (A) Lab scale in vitro experimental setup for the circulation of PA-spiked whole blood (from 
healthy donors). (B) A schematic representation of the in vitro circuit utilized for blood perfusion studies. 
(C) Vertical cross section of cryogel adsorbent column sitting in a plastic casing and cartoon illustration 
displaying antibody-antigen interactions inside interconnected porous cryogel structure. The adsorbent device 
is disposable, consisting of antibodies covalently coupled to the cryogel surface through protein-A which 
is located throughout the interconnected pores. Anthrax protective antigen in the blood is transported via 
convection and diffusion through the 10–100 μm pores in the cryogel matrix where they are bound.
www.nature.com/scientificreports/
6ScIentIfIc RepoRts |  (2018) 8:7518  | DOI:10.1038/s41598-018-25678-0
to PANG columns in comparison with the non-specific IgG mAb-bound AAm-AGE and tubing control, respec-
tively confirming specific binding capacity. These results are in line with our initial finding of an increased protein 
binding capacity in Valortim versus PANG antibodies from PBS and strongly indicate that Valortim-bound cryo-
gel columns are the more effective approach. Given this, only the Valortim-bound cryogel columns were used for 
the ex vivo studies. The efficiency of PA binding by cryogel immobilised antibodies is a combination of cryogel 
binding efficiency, correct orientation of the antibody with regards to protein-A interaction and the binding 
affinity of the antibody for its target on PA. From these studies, we can conclude that we are able to attach both 
glycosylated and non-glycosylated antibodies to a cryogel in a manner which allows them to capture their biolog-
ical target offering options for further functionalisation. Results also suggest a potential role for glycosylation in 
device efficacy although this has yet to be confirmed beyond the correlation observed in this study.
To summarise, a novel ex vivo technique for antibody-based PA capture using a macroporous polymer cryo-
gel column has been demonstrated. This approach presents new possibilities for the development of an effective 
antibody-based therapy against anthrax. We have shown using in vitro and in vivo models that a Valortim bound 
adsorbent haemoperfusion column can bind significant levels of PA from blood. While these results are prom-
ising further work is required to determine whether this approach is capable of effectively treating an infected 
individual. For example, by immobilising the antibody on the surface of the cryogel it is unlikely that it will be 
able to interact with PA which has already bound to host cells as is thought to happen when Valortim is deliv-
ered by injection18. The logical next step would be to compare the efficacy of this approach to that of the injected 
(unbound) Valortim with regards to its ability to protect against a lethal toxin challenge. Further studies will be 
needed to ascertain the survival benefit of the column in a combined PA + LF model, though this will require fur-
ther ethical consideration as in order to achieve reproducible detection levels of the proteins, the doses required 
have previously been shown to be universally lethal.
Anthrax specific glyco-engineered antibody-bound cryogel columns offer post-exposure protection against 
B. anthracis infection, making them an attractive candidate for therapeutic preparations aimed at providing effi-
cient and immediate anthrax toxin neutralisation. Glycosylated and immobilized PA capturing antibodies on a 
porous support may be of therapeutic value for alleviating the symptoms of anthrax toxin in infected individuals 
and for medium-term prophylaxis against infection. The ability to create cryogels which specifically bind indi-
vidual molecules through the incorporation of targeted specific antibodies raises the possibility of developing 
multifunctional cryogels capable of capturing a range of sepsis related factors. In addition, other adsorbents may 
be incorporated within a composite cryogel to extend the target range to sepsis related key pro-inflammatory 
mediators42 since the removal of these and pathogen produced virulence factors during late stage infection has 
been shown to impact patient survival43.
The Valortim-bound cryogel prototype tested in this proof-of-concept study using an in vivo haemoperfu-
sion model demonstrated significant depletion of PA levels from infected blood. Following further evaluation 
Figure 4. (A) Plasma and (B) whole blood PA concentration at indicated time points as determined by 
sandwich ELISA. Bar graphs shown are mean ± standard deviation (n = 3). Significant differences between 
cryogel groups were determined using a two-way ANOVA followed by Bonferroni’s post-hoc test to compare 
concentration of PA removed by cryogels. ‘*’Indicates significant different values within the same group 
(p < 0.05), while ‘#’values indicate statistically significant differences between the cryogel groups (p < 0.05).
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and technical development the device holds potential clinical interest particularly with the need for pertinent 
therapeutic agents against any conceivable future bioterrorism threats. Further, this approach to toxin capture 
via extracorporeal haemoperfusion may also provide an effective strategy for treating viral diseases caused by 
Ebola44, Zika, enveloped viruses including (therapy resistant) HIV, hepatitis B or C (induced liver failure), and 
even influenza.
Methods
Preparation of AAm-AGE cryogel and protein-A attachment. Monolithic macroporous poly(AAm-
co-AGE) cryogels containing epoxy surface functionality were synthesised by cryogelation technique at 
−12 °C by mixing the monomers 0.954 g acrylamide (AAm, 99%, Sigma, St Louis, MO, USA), 0.266 g of N, 
N’-methylenebis(acrylamide) (MBA, 99%, Sigma, St Louis, MO, USA) and 0.358 mL of allyl glycidyl ether (AGE, 
99% Sigma, St Louis, MO, USA) in deionized water at 8% w/v initial monomer concentrations. The monomer 
reaction mixture was transferred in to glass tubes (8 × 11 mm i.d.) just before free radical copolymerisation which 
was initiated by adding N, N, N’, N’-tetramethylethylenediamine (TEMED) (20 μL) and ammonium persulfate 
(APS) (20 mg). The co-polymerisation was carried out by freezing monomer-initiator mixture at −12 °C for 18 h 
in cryobath filled with an absolute ethanol. The cryogel columns were thawed at room temperature and washed 
repeatedly with deionized water to remove unreacted monomers and stored at 4 °C until further use. The resulting 
cryogel samples were named AAm-AGE cryogels.
To attach affinity ligand protein-A, the epoxy-functionalized monolithic AAm-AGE cryogel columns were 
first treated with ethylenediamine, then glutaraldehyde (GA). Briefly, 1 mL microporous cryogel columns having 
1.5 cm length and 9 mm internal diameter were connected to a peristaltic pump and washed simultaneously 
with 20 mL of water, at a flow rate of 1 mL/min and then with 0.2 M Na2CO3 (20 mL). Ethylenediamine solution 
(0.5 M in 0.2 M Na2CO3; 30 mL) was recirculated at a flow rate of 1 mL/min for 4 h and washed with water until 
pH was close to neutral. The cryogel columns were further washed with 20 mL 0.1 M sodium phosphate buffer at 
pH 7.2 and a solution of glutaraldehyde (5% v/v; 30 mL) in 0.1 M sodium phosphate buffer at pH 7.2 was recir-
culated through columns using peristaltic pump at a flow rate of 1 mL/min for 5 hours. For coupling protein-A 
affinity ligand through active aldehyde groups, the solution of protein-A (2 mg/mL; 12 mL) in 0.1 M sodium 
phosphate buffer at pH 7.2 was recirculated through each column at a flow rate of 1 mL/min at 4 °C for 24 h. 
Figure 5. (A) An ex vivo extracorporeal circuit incorporating cryogel columns. (B) The principle of the anti-PA 
sandwich ELISA used to measure plasma PA concentrations of PA left in a rat blood. (C) Measurable rat 
plasma PA concentrations immediately after administration by IV infusion (time = −60 minutes) or IP bolus. 
Time 0 was set at 60 minutes post IP bolus or at the end of the infusion period, with the remaining samples 
taken at hourly intervals. (D) Plasma PA concentration in circulating rat blood at 0 (at the end of a 60-minute 
IV infusion; administered initially at 100 μg/kg, followed by a maintenance infusion at 40 μg/kg for the final 
2 hours), 1 and 2-hour time points. Graphs shown are mean ± standard deviation (n = 6, p < 0.01).
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Freshly prepared sodium borohydride (NaBH4) solution (0.1 in sodium carbonate buffer, 30 mL) at pH 9.2 was 
recirculated through the cryogel column at a flow rate of 1 mL/min for 3 h to reduce Schiff ’s base formed during 
the coupling reaction.
Anthrax anti-toxin PANG and Valortim mAb binding and quantification. Anthrax anti-toxin 
mAbs, PANG (Fraunhofer USA Inc, Delaware, USA) and Valortim (PharmAthene Inc. Maryland, USA) were 
covalently immobilised on an AAm-AGE cryogel column through protein-A (from Staphylococcus aureus, 
Sigma, St Louis, MO, USA) as follows. The protein-A surface functionalised AAm-AGE cryogel columns were 
firstly pre-washed with 50 mM sodium borate solution at pH 8.2. PANG or Valortim antibody solution having a 
concentration of 2 mg/mL in 50 mM sodium borate was recirculated through cryogel columns using a peristaltic 
pump at 1.0 mL/min flow rate for 1 h while the pH was maintained at 8.2 throughout the recirculation period. 
Columns were again washed thoroughly with 50 mM sodium borate followed by 0.2 M triethanolamine at pH 
8.2. To form permanent crosslinking between surface protein-A and antibodies, a 5 mL (6.6 mg/mL) solution of 
crosslinking reagent dimethyl pimelimidate (DMP) in 0.2 M triethanolamine was recirculated through cryogel 
columns at a flow rate of 1 mL/min for 1 hour at pH 8.2. Columns were washed with the deionised water and the 
remaining active sites were blocked by washing columns with 5 mL 0.1 M ethanolamine solution at pH 8.2 for 
10 minutes. Columns were washed sequentially with deionized water, 1 M NaCl and finally with 0.1 M glycine to 
remove the un-bound antibody. Finally, columns were washed with deionised water, 1 M NaCl and 0.1 M glycine 
to remove any antibodies that remain non-covalently bound but not cross-linked, from the columns. Antibody 
bound cryogel columns were transferred to fridge and stored at 4 °C until further use.
The bicinchoninic acid (BCA) method was used to quantify the amount of protein-A and antibody immo-
bilised on AAm-AGE cryogel columns. Protein-A and antibody bound AAm-AGE columns were dried, finely 
powdered by grinding and suspended in water by ultra-sonication. Different amounts (20–100 μL) of this sus-
pension were prepared in triplicate and a 2 mL of the BCA solution was added to each tube. This mixture was 
then incubated at 37 °C for 30 minutes with constant shaking. Unmodified cryogel section samples were used as 
a control. 3 mL samples were withdrawn with and without centrifuging and transferred to spectrophotometer 
cuvettes. The absorbance was recorded at 562 nm using a UV spectrophotometer. A standard curve was prepared 
by plotting the absorbance of samples containing known concentrations of protein and IgG standards from 0, 200, 
400, 600, 800, and 1000 μg/mL.
Figure 6. Biochemical analysis results of (A) albumin, (B) ALT, (C) AST, (D) total protein, (E) glucose, (F) 
creatinine, and (G) urea concentrations in rat blood measured before PA IV infusion and at the end of the 
circuit. No statistically significant differences were noted.
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Porous morphology by SEM. Thin sections of cryogels (1 mm thickness and 9 mm diameter) were frozen 
at −80 °C for 8 hrs and then transferred to a Christ freeze-dryer to expel water from the cryogel samples for 8 
hrs at 0.200 mbar pressure under vacuum. The dried cryogel samples were mounted on an aluminium stub using 
double sided carbon tape and were sputter-coated with a 4 nm platinum layer for 3 minutes using a Quorum 
(Q150TES) coater instrument. Scanning electron microscopy (SEM) analysis was carried out at various magnifi-
cations (100, 500, and 1000×) using a Zeiss Sigma field emission gun SEM (Zeiss NTS) at an accelerating voltage 
of 5 kV.
Pore size distribution by mercury porosimetry and N2-adsorption. The low and high-pressure 
mercury intrusion measurements were performed to determine macropore (diameter ≤50 nm) size distribution 
by mechanical intrusion of mercury. Data were anlysed using PoreWin 6.0 software (Quantachrome Instruments, 
USA). The determination of pore size distribution in the mesoporous range was carried out using an Autosorb-1 
gas sorption analyser (Quantachrome Instruments, USA). Prior to the gas adsorption measurement, the freeze 
dried cryogel samples were out-gassed for 24 hrs at 50 °C to remove any entrapped air or moisture from the 
pores. The cryogel polymeric structure was preserved by using a relatively low temperature during out-gassing. 
The adsorbed and desorbed volumes of nitrogen gas by the test samples were measured using an Autosorb-1 gas 
sorption analyzer instrument (Quantachrome Instruments, USA) at a relative pressure at 77.4 K. Evaluation of 
sorption data were carried out using Quantachrome data analysis software (Quantachrome ASiQwin). Density 
Functional Theory (DFT) model was used to determine the mesoporous size distribution.
PA removal from fresh frozen human plasma and healthy donor whole blood. The structural 
gene for protective antigen was cloned into the vector pQE30 which has a 6× -Histidine affinity tag, expressed 
in E.coli and purified using a two-step process to achieve a level of purity >95% as described by Stokes et al.45. 
The ability of adsorbent monoliths to remove PA toxins was measured using human blood plasma (Cambridge 
Bioscience, UK) and healthy donor blood (n = 3) spiked with PA. Human blood samples were collected from 
healthy donors using appropriate informed consent procedures following ethics approval of experimental pro-
tocols by the University of Brighton ethics committee (HTA license 12583) and all experiments were performed 
in accordance with the relevant guidelines and regulations. PA removal studies were carried out using a lab scale 
experimental flow set up with PA spiked fresh frozen human plasma and freshly withdrawn human whole blood. 
For each recirculation experiment, syringe like plastic casing was packed with cryogel and connected in line with 
a peristaltic pump. The inlet and outlet tubing ports were connected to a reservoir containing 20 mL of plasma or 
blood spiked with anthrax toxin PA. An anthrax toxin adsorption device consisted of a syringe like plastic casing 
filled with highly interconnected polymeric AAm-AGE cryogel with immobilised Valortim or PANG antibodies 
capable of capturing anthrax toxin PA by antibody-antigen interaction. AAm-AGE cryogel columns (n = 3) hav-
ing 9 mm diameter and 1.5 cm length with maximum binding capacities for PANG and Valortim antibodies were 
chosen to evaluate PA removal from blood in vitro and ex vivo. A continuously circulating system was used to 
compare PA removal from plasma and blood by tubing only, unmodified AAm-AGE cryogel, protein-A modified 
non-specific IgG mAb-bound AAm-AGE cryogel along with PANG and Valortim bound AAm-AGE cryogel 
columns. A 20 mL reservoir volume of PA spiked plasma and blood at a concentration of 1 mg/mL was circulated 
through each column pre-wetted with phosphate buffered saline (PBS) at a rate of 2 mL/min. Samples were taken 
at 5, 10, 30, 45 and 60 minutes timed intervals. Blood samples were centrifuged at 3500 rpm for 15 min and plasma 
was removed. All samples were stored at −20 °C prior to analysis.
In vivo studies to determine PA removal from rat blood. All animal experiments were performed in 
accordance with the Animals (scientific Procedures) Act of 1986, which was revised according to the European 
Directive 2010/63/EU. All animals received humane care according to the criteria outlined in the Guide for the 
Care and Use of Laboratory Animals (National Institutes of Health publication 86–23; revised 1985). All proce-
dures and protocols were approved by the local University College London (UCL) Animal Welfare and Ethical 
Review Board (AWERB) and the UK Home Office. Adult male Sprague-Dawley rats (250–300 g, Charles River, 
UK) were anaesthetised under isofluorane (induction at 5% in oxygen, maintenance at 2% in air for the duration 
of the study), and had catheters placed in the left carotid artery and right jugular vein. Mean arterial pressure was 
recorded at hourly intervals (Biopac, US) and core body temperature recorded throughout the study. To main-
tain body temperature, the animals were placed on regulated heat mats and covered with insulating materials 
as required. Blood samples for biochemical testing and ELISA were collected into lithium heparin coated tubes 
for plasma biochemistry prior to, and at hourly intervals throughout the study. PA (List Biological Laboratories, 
US) was administered by intraperitoneal (IP) injection (100 μg/kg) or infused via the venous catheter for 1 hour 
at 100 μg/kg. In the filter studies, PA was infused as before for 1 hour prior to connection of the extracorporeal 
circuit and continued at 40 μg/kg for the remaining 2 hours of the study. After the initial 1-hour infusion period, 
the arterial catheter was connected to either a Valortim antibody bound or blank control cryogel columns (5 cm 
by 1 cm (length x diameter)) via a peristaltic pump. The blood was then returned to the animal via the catheter 
placed into the jugular vein. Flow rates throughout the 2-hour treatment period were set at 2 mL/min with the 
total circuit volume not exceeding 10% of the circulating blood volume of the animal (ca. 3 mL maximum). The 
circuit was pre-filled with heparinised saline solution (1000 U/L), with a saline bolus (ca. 3 mL) administered 
to the animal at the start of treatment to prevent hypotension. At the termination of the study, blood and tissue 
samples were collected under terminal anaesthesia. Blood samples for biochemistry and PA analysis were stored 
on ice before centrifugation (3500 rpm, 10 minutes, 4 °C) and stored at −80 °C. Plasma biochemistry (glucose, 
urea, albumin, total protein, ALT, AST, creatinine) was assessed using an automated COBAS system (Roche, UK) 
following manufacturer’s instructions.
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An anti-PA sandwich ELISA analysis for PA adsorption. Plasma samples from the adsorption and 
blood samples from animal model studies underwent a 1 in 2 dilution in assay diluent. Protective antigen con-
centrations present in the plasma were analysed by using an anti-PA sandwich ELISA. Briefly, a PolySorp Nunc 
plate (Thermo Sc., Product No 446140) was coated with the PANG antibody at a concentration of 2 μg/mL in 
0.1 M bicarbonate-carbonate buffer (0.1 M NaHCO3, 0.1 M Na2HCO3), pH 9.6. 100 μL were added per well and 
the plate was incubated overnight in the fridge. The plate was washed 6 times 350 μL of PBS + 0.1% Tween-20. 
The Protective Antigen standard was diluted to a 5–200 ng/mL range in PBS + 0.3 M NaCl + 0.1% Tween-20. 
100 μL was added per well and the ELISA plate was incubated for 90 minutes at room temp. The plate was washed 
3 times 350 μL of PBS + 0.1% Tween-20. The biotinylated Valortim antibody (prepared using the ImmunoProbe 
Biotinylation Kit, Sigma, Product No. BK101, according to manufacturer’s instructions) was diluted to a con-
centration of 4.4 μg/mL in PBS + 0.3 M NaCl + 0.1% Tween-20. 100 μL was added per well and the ELISA plate 
was incubated at room temperature for 90 minutes. The ELISA plate was washed three times using 350 μL of 
PBS + 0.1% Tween-20. The Streptavidin-Peroxidase Polymer (Sigma, Product No. S2438) was diluted 1:32000 
in PBS + 0.3 M NaCl + 0.1% Tween-20. 100 μL was added per well and incubated the ELISA plate for 90 minutes 
at room temperature. The plate was washed again three times with 350 μL of PBS + 0.1% Tween-20. 100 μL of 
TMB (3, 3′, 5, 5′-Tetramethylbenzidine) substrate solution (Thermo Scientific, Product No 34021) was added per 
well and the plate was incubated in the dark for 15 minutes at room temperature. The reaction was stopped by 
adding 100 μL of 1 N HCl to each well. The absorbance was read at 450 nm. The absorbance (optical density) was 
measured using an ELISA plate reader (ELX 800 microplate reader; BioTek Instruments, Inc., Winooski, VT) at 
450 nm. All standards and experimental samples were run in triplicate. The standard curve was constructed by 
plotting absorbance values at 450 nm against the known PA concentrations.
Statistical analysis. All quantitative data are expressed as mean ± standard deviation. Statistical analysis 
was performed using GraphPad Prism 5.0 (GraphPad Software, USA). Statistical significance was determined by 
two-way ANOVA with the Bonferroni post-test. P values less than 0.05 were considered statistically significant.
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